<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Medical devices (A7-0324/2013 - Dagmar Roth-Behrendt) - Tuesday, 22 October 2013</title><meta name="title" content="Verbatim report of proceedings - Medical devices (A7-0324/2013 - Dagmar Roth-Behrendt) - Tuesday, 22 October 2013" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2013 - Source: European Parliament" /><meta name="available" content="22-10-2013" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Medical devices (A7-0324/2013 - Dagmar Roth-Behrendt) - Tuesday, 22 October 2013" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2013-10-22-ITM-009-04_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2013-10-22-ITM-009-04_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-10-22-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22-ITM-009-03_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22-ITM-009-05_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2013-10-22-ITM-009-05_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2013-10-22_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2013-10-22_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2012/0266(COD)">2012/0266(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0324/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0324_EN.html" class="ring_ref_link">A7-0324/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p>
                        <a href="/doceo/document/PV-7-2013-10-22-ITM-004_EN.html" class="ring_ref_link">PV 22/10/2013 - 4</a><br />
                        <a href="/doceo/document/CRE-7-2013-10-22-ITM-004_EN.html" class="ring_ref_link">CRE 22/10/2013 - 4</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2013-10-22-ITM-006-04_EN.html" class="ring_ref_link">PV 22/10/2013 - 6.4</a><br />
                        <a href="/doceo/document/CRE-7-2013-10-22-ITM-006-04_EN.html" class="ring_ref_link">CRE 22/10/2013 - 6.4</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                        <a href="/doceo/document/PV-7-2014-04-02-ITM-018-11_EN.html" class="ring_ref_link">PV 02/04/2014 - 18.11</a><br />
                        <a href="/doceo/document/CRE-7-2014-04-03-ITM-009-10_EN.html?textTabled=A-7-2013-0324" class="ring_ref_link">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2013-0428_EN.html" class="ring_ref_link">P7_TA(2013)0428</a><br />
                        <a href="/doceo/document/TA-7-2014-0266_EN.html" class="ring_ref_link">P7_TA(2014)0266</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Tuesday, 22 October 2013 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 9.4. Medical devices (<a href="/doceo/document/A-7-2013-0324_EN.html">A7-0324/2013</a> - Dagmar Roth-Behrendt) </td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:20:30&amp;playerEndTime=20131022-13:28:37" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:20:30&amp;playerEndTime=20131022-13:28:37" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:20:30&amp;playerEndTime=20131022-13:28:37" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td></tr></table>
<a name="2-223-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Oral explanations of vote</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-224-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/21818.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:20:55&amp;playerEndTime=20131022-13:22:22" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Paolo Bartolozzi (PPE). - </span></span>  Signora Presidente, onorevoli colleghi, abbiamo votato oggi sulla proposta di regolamento relativa ai dispositivi medici.</p>
<p class="contents">Si tratta di un <span class="italic">dossier </span>importante che, parallelamente alla proposta sui dispositivi medico-diagnostici in vitro, si propone di procedere a un riesame del contesto normativo di riferimento, che era fermo agli anni '90, per rafforzarlo e superare le divergenze interpretative nei vari Stati membri.</p>
<p class="contents">In seguito ad alcuni scandali sanitari – com'è già stato ricordato – è stato ritenuto importante intervenire per la sicurezza dei pazienti. Oggi abbiamo quindi espresso un nostro voto positivo a un testo che innanzitutto si è posto come obiettivo primario la difesa della salute dei pazienti europei, ma anche una migliore e maggiore definizione delle garanzie poste a loro tutela, un monitoraggio più rigoroso, una più precisa esplicitazione per gli obblighi dei fabbricanti e degli operatori sanitari. </p>
<p class="contents">Insomma, è stata rivolta una grande attenzione al tempo stesso al settore dei dispositivi medici al fine di garantire e tutelare la concorrenzialità, vista la sua estrema importanza in termini di innovazione e occupazione per la realtà europea, e alla tutela e sicurezza dei pazienti. L'auspicio è che si continui su queste linee nelle prossime fasi negoziali.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-225-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96664.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:22:29&amp;playerEndTime=20131022-13:23:29" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Anna Rosbach (ECR). - </span></span>  Fru formand! Jeg tillader mig at tale om de vægtigste betænkninger sammen. Jeg har stemt for at sætte patientsikkerheden som førsteprioritet. Derfor har jeg støttet uanmeldte inspektioner og højere krav for godkendelse af medicinsk udstyr. For mig og mit parti er det vigtigt med en klar sporbarhed af implantater og åben information omkring produkterne. Derfor har jeg også støttet bedre rådgivning i forbindelse med genetisk test. Derimod har jeg stemt imod industriens ret til at genanvende engangsudstyr. Jeg havde allerhelst set et forbud mod denne praksis, og jeg forstår simpelt hen ikke de kollegaer, der har kæmpet for genanvendelse af udstyr produceret til kun at blive brugt én gang, da sikkerheden omkring genbrug kan være tvivlsom. I mine øjne er det at spille hasard med syge menneskers tillid og helbred. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-226-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28116.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:23:35&amp;playerEndTime=20131022-13:24:54" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marian Harkin (ALDE). -</span></span>   Madam President, this report on medical devices is a balanced one which, like the in vitro report, puts patient safety first. Recent events such as the PIP scandal and the issue of certain hip replacements causing damage to bones are clear indications that we needed to review our legislation. One of the issues which was very clear was that all the different notified bodies in the different Member States were not operating at the same high level and that such gaps in regulatory controls had to be dealt with – and they were – in this proposal.</p>
<p class="contents">We now have a new medical devices coordination group and the new assessment committee for medical devices. Together they will ensure that there are no gaps in the very necessary regulatory controls. The report is proportionate, and we recognise that the PIP scandal was fraud. I think we have ensured an effective streamlined authorisation process which gives certainty to manufacturers and puts patient safety first.</p>
<p class="contents">Like Mr Higgins, I represent a country where there are 26 000 jobs in the medical devices sector – in Athlone, Sligo, Galway and elsewhere. Today we have helped to ensure the continuation of those jobs while at the same time putting patient safety first.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-227-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1941.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:24:57&amp;playerEndTime=20131022-13:26:10" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Roberta Angelilli (PPE). - </span></span>  Signora Presidente, come dimenticare l'incidente delle protesi difettose impiantate a migliaia di persone? È gravissimo che un incidente di questa portata sia potuto accadere.</p>
<p class="contents">La salute è un diritto fondamentale e deve essere una priorità assoluta, per questo concordo sulla necessità di sottoporre a controlli più severi il materiale ad uso medico, migliorandone la qualità e la sicurezza proprio per ridare fiducia ai pazienti. Ciò può avvenire solo in un quadro giuridico chiaro, certo e rafforzato, quindi: garanzie e tutela per i consumatori, tracciabilità e precisi obblighi per i fabbricanti. </p>
<p class="contents">Tutto questo a sostegno dell'innovazione e della competitività di un settore che in Europa conta oltre mezzo milione di dipendenti, con un volume d'affari di oltre cento miliardi di euro annui. Attenzione però all'appesantimento delle procedure, soprattutto a scapito delle piccole e medie imprese.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-228-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96951.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:26:14&amp;playerEndTime=20131022-13:27:15" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diane Dodds (NI). - </span></span>  Madam President, the health and wellbeing of our constituents are a top priority for all of us as legislators, and I welcome much of what is in this report before Parliament today. Confidence in all aspects of health care, especially in the safety of medical devices and of medical procedures, is paramount to both healthcare professionals and patients.</p>
<p class="contents">As technology evolves and further innovation brings yet more progress in the field of medicine, we ought to ensure that such innovation does not come at the expense of patients’ safety. Information is also vital, and I believe that for many patients there is a vacuum of information – whether relating to benefits or risks – regarding the medical devices which are becoming more prevalent in treatment. That is a situation that must be addressed, and I believe this report can go some way to doing this.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-229-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96668.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20131022-13:27:16&amp;playerEndTime=20131022-13:28:36" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Seán Kelly (PPE). - </span></span>  Madam President, like my colleagues Ms Harkin and Mr Higgins, I too give my general approval to these recommendations – both this report and the previous one. Certainly it is right that we should try to eliminate the duplication of research and studies, and that we should eliminate inconsistencies across the European Union and help to complete the internal market. Many of the proposals go a long way to ensuring that this happens.</p>
<p class="contents">However, I am pleased that we have got a mandate to continue discussions with the Council, and I would hope that some of the concerns that industry has will be taken on board there. I met some representatives from my country of industries that account for EUR 7 billion in exports and employ 26 000 employees. They feel that, if it is implemented as it stands, it could lead to a three-year delay in approval for new products. This would not be good for Europe and not good for Ireland, and it certainly does not make more sense. I hope this can be addressed.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-230-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Written explanations of vote</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-230-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Acolho com satisfação a proposta da Comissão de rever o atual quadro regulamentar relativo aos dispositivos médicos. A revisão, a meu ver, era especialmente necessária, dado tratar-se de um quadro com vinte anos, tendo-se introduzido muitas melhorias à atual legislação. Contudo, considero que ainda se deveria introduzir no texto muitas outras alterações. Entendo que a Comissão propõe uma estrutura de texto não totalmente satisfatória, dado que não reflete a sequência de atividades que precisam de ser efetuadas antes de um dispositivo médico poder ser utilizado com segurança. No segundo capítulo já se faz referência à disponibilização dos dispositivos, à sua livre circulação, ou mesmo ao reprocessamento, antes mesmo de se mencionar a classificação dos dispositivos ou a seleção do procedimento de aprovação. A ordem utilizada também coloca a ênfase na colocação dos dispositivos no mercado e na sua livre circulação dentro da UE, deixando para segundo plano considerações como a segurança dos doentes e a saúde pública (classificação, procedimento de aprovação e investigações clínicas).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-231-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96702.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elena Oana Antonescu (PPE), </span></span>  <span class="italic">în scris</span><span class="bold">. − </span>În lumina scandalurilor recente, cum ar fi cel al implanturilor mamare PIP, avem nevoie de o monitorizare mai strictă, de organisme de certificare puternice şi de o mai bună trasabilitate a dispozitivelor medicale, pentru a proteja pacienţii. Stabilirea unor obligaţii clare pe care producătorii şi operatorii economici trebuie să le respecte, înăsprirea normelor privind evaluarea clinică, crearea unui portal UE pentru raportarea incidentelor grave, îmbunătăţirea transparenţei informaţiilor pentru pacienţi şi consolidarea normelor de trasabilitate sunt paşi importanţi în acest sens. Salut propunerea adoptată astăzi, pentru că are potenţialul de a creşte gradul de protecţie a sănătăţii cetăţenilor, de a înlătura obstacolele din calea pieţei interne şi de a îmbunătăţii transparenţa în informarea pacienţilor. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-231-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96680.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zigmantas Balčytis (S&amp;D), </span></span>  <span class="italic">raštu</span><span class="bold">. − </span>Balsavau už šį siūlymą, kurio tikslas –sugriežtinti medicinos prietaisų kontrolę. Komisija yra pasiūliusi du skaidresnius ir labiau prie mokslo ir technologijų pažangos priderintus šios srities reglamentus: reglamentą dėl medicinos prietaisų ir reglamentą dėl <span class="italic">in vitro</span> diagnostikos medicinos prietaisų. Šiuo metu rinkoje yra daugiau kaip 500 tūkst. įvairių rūšių prietaisų, kurios vertė – maždaug 95 mlrd. eurų. Jie apima tokius produktus kaip pleistrai, kontaktiniai lęšiai, rentgeno aparatai, širdies stimuliatoriai, ŽIV kraujo testai ir kt. Pritariu siūlomoms taisyklėms, kuriomis bus patobulinti šie rinkoje esantys medicinos gaminiai, ir sugriežtinta <span class="italic">in vitro</span> diagnostikos medicinos prietaisų kontrolė, ypač po Europoje kilusio skandalo dėl nekokybiškų krūtų implantų ir klubo sąnario protezų. Pritariu siūlymams dėl griežtesnės nepriklausomų vertinimo įstaigų priežiūros, aiškesnių gamintojų, importuotojų ir platintojų teisių ir pareigų, išplėstos medicinos prietaisų duomenų bazės. Labai svarbu, kad būtų užtikrintas geresnis prietaisų atsekamumas visoje tiekimo grandinėje bei galimybė greitai ir veiksmingai reaguoti į saugos problemas.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-231-562"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/5956.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Regina Bastos (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>O presente relatório visa regulamentar as normas de segurança, a qualidade e a eficiência dos dispositivos médicos que são colocados no mercado na União Europeia. Acontecimentos recentes, como o escândalo sobre os implantes mamários fraudulentos em silicone, trouxeram estas questões à atenção do público. A legislação europeia que regulamenta este setor tem 20 anos e carece de uma revisão. Deste modo o novo regulamento garante maior segurança para os dispositivos médicos, não só para os pacientes, mas também para os profissionais de saúde que os utilizam e manipulam, assim como melhora o acesso do público e dos profissionais de saúde a informações importantes sobre os dispositivos médicos. Pelo exposto, o presente relatório mereceu o meu apoio.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-231-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28214.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Bennahmias (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai approuvé aujourd'hui les deux rapports concernant la mise à jour des règlements relatifs aux dispositifs médicaux. Fin 2011, le scandale des implants mammaires défectueux PIP a révélé le manque de coopération entre États membres et le dysfonctionnement du système de traçabilité des dispositifs médicaux. Plus de 400 000 implants mammaires de la société française PIP ont en effet été commercialisés dans le monde en dépit du non-respect des critères de qualité. Aujourd'hui le Parlement s'est prononcé pour de nouvelles exigences: il s'agit d'améliorer la protection des patients en renforçant la traçabilité et les contrôles pour éviter un nouveau scandale de ce type. Cela passe notamment par le renforcement de l'accès aux données cliniques afin de mieux connaitre les produits mais aussi par la mise en place d'une "carte d'implant" pour les receveurs d'implants ou encore par un plus grand partage d'informations entre les autorités nationales. J'ai une inquiétude sur la question de l'accessibilité des tests à hauts risques: il ne faudrait pas que la nouvelle législation restreigne les possibilités pour les États membres de faciliter la disponibilité de tests (notamment dépistage HIV) au public (notamment à haut risque).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-231-687"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/38610.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Слави Бинев (EFD), </span></span>  <span class="italic">в писмена форма</span><span class="bold">. − </span>Гласувах в полза на предложението на Комисията за нов регламент относно преразглеждане на съществуващата нормативна уредба за медицинските изделия, тъй като преразглеждане на уредбата, която е в сила от двадесет години, беше особено необходимо и в действащото законодателство бяха въведени много подобрения. Против бях, обаче, доклада на Дагмар Рот-Беренд, защото предвижданият незадължителен регламент на настоящия етап е нерентабилнен съобразно пазара на изделията в отделните страни членки. </p>
<p class="contents">Още по-сложен за изпълнение го прави и факта, че не съществуват или съществуват твърде малко на брой общи методи на оценяване (нормативни насоки) в тази област за производителите и за нотифицираните органи. По отношение на одобрението, разпространението и проследяването на медицинските продукти, смятам, че всяка държава членка трябва да продължи да прилага собственото си национално законодателство, съобразно правната си традиция и утвърдените практики.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-231-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/111126.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Arkadiusz Tomasz Bratkowski (PPE), </span></span>  <span class="italic">na piśmie</span>. <span class="bold">− </span>W głosowaniu poparłem sprawozdawczynię w sprawie wyrobów medycznych, gdyż w pełni zgadzam się, że bezpieczeństwo i zdrowie pacjentów są niekwestionowanym priorytetem w dziedzinie zdrowia publicznego w Unii Europejskiej. Do zagwarantowania wysokiego poziomu zdrowia jej obywateli konieczne jest stworzenie przejrzystych i dostosowanych do postępu naukowego przepisów dotyczących rynku wewnętrznego w obszarze wyrobów medycznych. Ponadto niezbędne jest wprowadzenie zaostrzonych kontroli w tej dziedzinie, co zagwarantuje, że na rynek europejski będą trafiały tylko bezpieczne wyroby medyczne. </p>
<p class="contents">Trzeba jednak zaznaczyć, że w przypadku innowacyjnych wyrobów medycznych podwyższonego ryzyka, decyzja o ich wprowadzeniu na rynek nie może zależeć jedynie od jednostki notyfikowanej. Każdy wchodzący na rynek produkt medyczny powinien być podanny jednakowej ocenie według tych samych kryteriów. W chwili obecnej Unia Europejska nie dysponuje wspólnymi metodami weryfikacji, zarówno w przypadku producentów, jak i jednostek notyfikowanych. Mając powyższe na uwadze, jestem za ustanowieniem nowych mechanizmów oceny w tej dziedzinie, które zredukowałyby procedury administracyjne, a jednocześnie stałyby na straży najwyższego poziomu bezpieczeństwa pacjentów oraz pracowników służby zdrowia.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-232-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96716.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zuzana Brzobohatá (S&amp;D), </span></span>  <span class="italic">písemně</span>. <span class="bold">− </span>Zpráva navrhuje přísnější monitorování, posílení certifikačních orgánů a zlepšení sledovatelnosti zdravotnických prostředků. Nové nařízení by mělo srovnat rozdíly ve výkladu stávajících pravidel a posílit ochranu veřejného zdraví. Zdravotnické prostředky od náplastí, kontaktních čoček a těhotenských testů až po stomatologický výplňový materiál, rentgenové přístroje, kardiostimulátory, prsní implantáty, náhrady kyčelního kloubu a krevní testy na HIV jsou regulované v rámci EU ve své stávající formě již 20 let. Vítám revizi této regulace a její obnovení k zajištění většího bezpečí pacientů. V návaznosti na skandály týkající se defektních prsních implantátů a náhrad kyčelních kloubů se domnívám, že jsou přísnější kontroly zdravotnických prostředků nezbytné pro lepší ochranu pacientů. Proto jsem tuto zprávu podpořila.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-232-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96867.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria Da Graça Carvalho (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Congratulo-me com o relatório hoje aprovado pelo Parlamento Europeu especialmente pelo resultado alcançado. Visa o melhoramento da segurança do paciente. A questão da segurança dos cidadãos e das cidadãs europeus terá que vir em primeiro lugar e ser o centro das preocupações deste relatório</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-232-562"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28148.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Castex (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Le scandale des implants mammaires, c’est 500 000 prothèses portées dans le monde, 8 000 retraits d’implants, 48 cas de cancer avérés. Ces nombreux drames nous obligeaient à revoir en profondeur ces textes qui concernent directement la santé des Européens. Notre réaction a été à la hauteur, là où la Commission européenne a d’abord pêché par sa lenteur, puis par des propositions initiales insuffisantes en termes de sécurité et de santé publique. Initialement, nous avions plaidé pour une autorisation de mise sur le marché pour les dispositifs médicaux implantables à haut risque. Notre proposition était soutenue par les Verts et la GUE, mais elle n’a pas survécu à la très forte opposition de la droite, des libéraux et des conservateurs. Les changements introduits représentent tout de même des avancées dont je me félicite.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-232-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/113597.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Minodora Cliveti (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. − </span>Rolul dispozitivelor medicale în domeniul îngrijirii sănătăţii este esenţial și, în acest context, salut propunerea de revizuire a cadrului de reglementare existent privind dispozitivele medicale. Avem nevoie, la nivelul Uniunii Europene, de îmbunătățirea legislației în vigoare și de stabilirea unor standarde înalte de calitate și siguranță pentru dispozitivele medicale, asigurând astfel un nivel crescut de protecție a sănătății pentru pacienți, utilizatori și personalul manipulant. </p>
<p class="contents">Revizuirea cadrului de reglementare existent va spori transparența informațiilor pentru pacienți și pentru personalul medical și va întări regulile privind informațiile despre sursa echipamentelor medicale, fără să creeze greutăți suplimentare micilor producători inovatori. </p>
<p class="contents">Prin votul de astăzi, Parlamentul European s-a pronunțat pentru o monitorizare și proceduri de certificare mai stricte ale echipamentelor medicale de tip implant mamar și de șold, în scopul de a asigura respectarea regulilor și identificarea sursei echipamentului. Consider că publicitatea pentru intervențiile chirurgicale cosmetice, cum ar fi implantul mamar, ar trebui să fie mai bine reglementată pentru a se asigura că pacienții sunt pe deplin conștienți de riscuri, precum și de beneficii. Au fost stabilite și responsabilități mai clare pentru reutilizarea dispozitivele de unică folosință precum și un mecanism de evaluare mai eficace și adaptat pentru dispozitivele cu risc.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-232-687"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Lara Comi (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Negli ultimi anni, la procedura di valutazione della conformità dei prodotti medici ha mostrato notevoli lacune. Ne è una dimostrazione evidente lo scandalo delle protesi mammarie emerso nel 2011, quando si è scoperto che oltre mezzo milione di donne in tutto il mondo, hanno ricevuto protesi difettose con gravi rischi per la loro salute. Casi del genere non si devono più verificare. Ho dunque votato favorevolmente a questa relazione che mira a migliorare la vigilanza del mercato, rafforzare e razionalizzare il sistema degli organismi incaricati delle valutazioni di conformità (soprattutto sui prodotti che presentano i maggiori rischi), e garantire maggiore trasparenza e tracciabilità.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-232-718"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112071.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Emer Costello (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I supported Parliament’s amendments to the proposed medical devices regulation. Over 3 500 people in Ireland were fitted with defective metal hip replacements between 2003 and 2010 while more than 1 500 women in Ireland received faulty PIP breast implants, containing industrial silicone instead of medical-grade fillers. Hundreds of thousands more have been similarly affected across Europe. These faulty medical devices then have to be replaced, causing additional distress to patients. We clearly need a better Europe-wide regulatory framework for medical devices, one that guarantees that only devices that are safe for patients are authorised, and that promotes safe innovation in this sector. We need a state-of-the-art assessment procedure for all medical devices – from hip and breast implants to surgical instruments, as well as reinforced controls over the 80 or so ‘notified bodies’ across Europe which are responsible for assessing the performance and safety of medical devices, and which should operate to common standards. I would now urge the Council to work closely with Parliament so that we can reach overall agreement on a new regulation and reassure the public concerning the safety of medical devices used across Europe.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-232-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/72775.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Rachida Dati (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai voté pour une plus grande transparence et une meilleure traçabilité des dispositifs médicaux, et un meilleur accès à l'information pour les patients. Il s'agit d'une avancée significative pour la santé publique européenne, et pour une sécurité accrue des patients.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-233-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/117477.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mark Demesmaeker (Verts/ALE), </span></span>  <span class="italic">schriftelijk</span><span class="bold">. − </span>Vandaag hebben we gestemd over twee verordeningen die de veiligheid van medische hulpmiddelen moeten verhogen. Jammer genoeg heeft het Parlement niet gekozen voor een model met één controle op Europees niveau voor de meest riskante hulpmiddelen. De uitgewerkte conformiteitsprocedure voor riskante hulpmiddelen die we vandaag hebben goedgekeurd is te complex en bevat te veel uitzonderingen. Als we de Europese patiënten echt zekerheid willen bieden, en willen vermijden dat een situatie als het PIP-schandaal ooit nog voorkomt, moeten we op termijn evolueren naar een centrale Europese beoordelingsprocedure vooraleer riskante hulpmiddelen op de markt kunnen komen. </p>
<p class="contents">Een tweede punt dat ik wil benadrukken is het belang van goede regels voor het gebruik van genetische tests (DNA tests). Deze tests zijn vaak van bedenkelijke kwaliteit, de interpretatie van het resultaat is niet vanzelfsprekend, en de gevolgen kunnen verstrekkend zijn voor de persoon en zijn familie. Een genetische test met een voorspellende functie is niet iets om vrijblijvend mee om te springen. Ik ben dan ook blij dat het Parlement met zeer grote meerderheid heeft gestemd om de nodige begeleiding door een medisch expert voor en na de test verplicht te maken.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-233-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4335.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marielle de Sarnez (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Le scandale des prothèses mammaires PIP a mis en lumière les lacunes du système européen de contrôle des dispositifs médicaux. Ces produits, contrairement aux médicaments, ne nécessitent pas d'autorisation préalable de mise sur le marché d’une autorité sanitaire, il est donc indispensable de développer des règles de certification plus strictes, qui placent la sécurité des patients au premier plan. Avec la révision de ce système, les dispositifs médicaux présentant le plus de risques - comme ceux destinés à être implantés dans le corps humain-, seront désormais contrôlés par des organismes spécialisés. L'accès aux données cliniques des dispositifs permettra une meilleure surveillance du marché. Lorsqu'un incident se produit dans un État, un système d'alerte favorisera une réaction rapide dans les autres pays européens. Le retraitement de certains dispositifs médicaux à usage unique peut exposer les patients à des risques sanitaires. Cette pratique est aujourd’hui interdite en France et les États qui le souhaitent pourront faire de même. Les dispositifs de diagnostic in vitro verront également leurs règles de sécurité renforcées par la mise en place, notamment, d’un comité d’éthique. Ces nouvelles mesures permettront de restaurer la confiance des consommateurs dans le secteur, tout en préservant sa capacité d'innovation.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-233-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4550.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jill Evans (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I voted in favour of this report. Medical devices comprise more than half a million different products, ranging from adhesive bandages to pacemakers. The European market is estimated to be around EUR 100 billion annually. The current legislation on medical devices was introduced in the 1990s and a review of the legislation was planned for many years. However recent scandals, especially the one concerning breast implants, showed the need for urgent reform. This is an important issue for my constituents in Wales and I have received several letters in relation to this.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-233-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Göran Färm, Anna Hedh, Olle Ludvigsson, Jens Nilsson och Marita Ulvskog (S&amp;D), </span></span>  <span class="italic">skriftlig</span><span class="bold">. − </span>Vi svenska socialdemokrater välkomnar moderniseringen av EU:s regelverk för medicintekniska produkter. Människor ska kunna lita på att de produkter som finns på marknaden är ordentligt testade och säkra. Patientsäkerheten och folkhälsan fordrar att EU:s regelverk speglar den snabba utvecklingstakt som råder på marknaden. Nuvarande regelverk är föråldrat och har inte förnyats sedan mitten på 1990-talet. Detta har lett till stora skillnader i nationella regelverk mellan medlemsländer samt osäkerhet kring reglerna för vissa produkter.</p>
<p class="contents">Med detta i beaktande stöder vi att särskilt angivna högriskprodukter med indirekt medicinsk funktion inkluderas i det medicintekniska regelverket. Trots att vi generellt manar till försiktighet i breddandet av definitionen av medicintekniska produkter anser vi att det i detta fall är motiverat. För oss är det viktigaste att patienthälsan tryggas. Utifrån textens utformning valde vi även att rösta för vissa ytterligare horisontella förändringar av regelverket, bland annat det nya tillsynssystem som föreslagits för anmälda organ.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-233-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96977.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Diogo Feio (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>A regulamentação aplicável aos dispositivos médicos tem 20 anos, e embora tenha estabelecido os princípios basilares para o fabrico e a comercialização destes, precisa de ser melhorada e adaptada à realidade actual. Uma vez mais, a proposta pretende garantir elevados padrões de segurança para os dispositivos médicos e melhorar o procedimento aplicável à notificação de incidentes e ações corretivas de segurança, de modo a evitar que um caso como o da PIP se possa repetir no espaço na União, com o óbvio prejuízo dos utilizadores de dispositivos médicos. Ao encontrar tais preocupações reflectidas no texto, voto-o favoravelmente.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-233-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96899.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">José Manuel Fernandes (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>O relatório elaborado pela colega Dagmar Roth-Behrendt debruça-se sobre a proposta de regulamento do Parlamento Europeu e do Conselho que altera a Directiva 2001/83/CE, o Regulamento (CE) n.º 178/2002 e o Regulamento (CE) n.º 1223/2009 e visa regulamentar as normas de segurança, a qualidade e a eficiência dos dispositivos médicos que são colocados no mercado na UE. Existem centenas de milhares de tipos de dispositivos médicos atualmente disponíveis no mercado na União Europeia como, por exemplo, os pensos rápidos, as seringas, os cateteres, os dispositivos de recolha de sangue, os implantes sofisticados e as tecnologias de suporte de vida. O quadro legislativo atual já tem 20 anos e uma revisão é agora necessária depois das insuficiências detetadas nos últimos anos, tais como a falta de transparência e a rápida aprovação e colocação no mercado de dispositivos médicos. A falta da investigação em doentes e os dados clínicos insuficientes colocam em última analise os próprios doentes em risco. Assim, importa agora garantir um novo regulamento que garanta que os dispositivos médicos são seguros, não só para os pacientes, mas também para os profissionais de saúde que os utilizam ou manipulam, sem esquecer os leigos que entram em contacto com os dispositivos mencionados.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-234-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">João Ferreira (GUE/NGL), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Depois dos problemas graves registados em vários países relativamente aos implantes mamários de silicone e aos implantes metálicos para as ancas, a Comissão Europeia elaborou uma proposta de regulamento sobre dispositivos médicos. Os dispositivos médicos considerados neste regulamento dizem respeito a qualquer instrumento, aparelho, equipamento, máquina, implante ou <span class="italic">software</span> desenhados para diagnóstico, prevenção, monitorização ou tratamento de doenças, que vão desde as simples ligaduras até aos instrumentos mais complexos de suporte de vida como <span class="italic">pacemakers</span> ou implantes de vária ordem. O regulamento pretende aumentar a transparência dos processos, melhorar a informação aos pacientes, melhorar o controlo sob os organismos notificados, subcontratados e subsidiados, estabelecer requisitos para pessoal interno das autoridades nacionais e organismos notificados e regras mais restritas para os dispositivos que podem ser reprocessados. O objetivo da proposta foi alargado também aos dispositivos médicos para fins estéticos, visando-se melhorar a rastreabilidade para permitir, por exemplo, uma retirada rápida dos dispositivos do mercado. O resultado final da votação enfraqueceu substancialmente a proposta que saiu da comissão especializada – do Ambiente, Saúde Pública e Segurança Alimentar. Ainda assim, são dados passos positivos face a uma situação cuja persistência é inaceitável e perigosa, pelo que votámos favoravelmente.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-234-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28126.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Christofer Fjellner (PPE), </span></span>  <span class="italic">skriftlig</span><span class="bold">. − </span>Vi stöder den harmonisering och uppstramning av regelverken för medicintekniska produkter som nu sker. Eventuella förbud mot farliga ämnen bör dock ske efter vetenskaplig nytta/risk-analys på myndighetsnivå. Inte genom politiska beslut och en nollvision mot risker. Konsekvensen av det beslut Europaparlamentet fattat blir att farliga ämnen fasas ut omedelbart, om det inte finns tekniska eller säkerhetsmässiga begränsningar som omöjliggör detta. I de fall som det gör det ska EU-kommissionen och Europaparlamentet fatta beslut om undantag i maximalt fyra år. Vi ser stora problem med detta, både vad gäller produkternas funktion, säkerhet och kostnad.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-235-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102886.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Ildikó Gáll-Pelcz (PPE), </span></span>  <span class="italic">írásban </span><span class="bold">− </span>A közelmúltban sajnos túl sok veszélyes orvosi eszköz, például csípőprotézisek, kerültek beültetésre az Unióban. Úgy gondolom, hogy azáltal, hogyha a javaslat szerint a tagállami hatóságok szigorúbban ellenőrizhetnék az orvostechnikai eszközök piacra kerülése előtti teszteket végző cégeket, a betegek biztonsága Európa-szerte is jelentősen javulni fog, így szavazatommal támogattam a jelentést.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-235-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28208.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nathalie Griesbeck (ALDE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Le vote de ces textes sur les dispositifs médicaux et sur les dispositifs médicaux de diagnostic in vitro est important puisque ces textes auront des répercussions directes sur la santé publique européenne et donc sur la vie quotidienne des citoyens de l'Union. À la suite de la série de scandales liés à la santé dont l'affaire des prothèses mammaires PIP, il m'apparait essentiel que la nouvelle législation comble les lacunes actuelles, renforce la protection des consommateurs et restaure la confiance des patients en la médecine. Les textes que j'ai votés soutiennent des mesures plus strictes en termes de surveillance, de certification et de traçabilité des dispositifs médicaux. Les contrôles seront dorénavant beaucoup plus rigoureux pour les dispositifs médicaux de diagnostic in vitro ou les autres. Nous avons également décidé de réglementer le retraitement des dispositifs à usage unique de façon à mieux assurer la sécurité des patients.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-234-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96952.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sylvie Guillaume (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Après plusieurs scandales, comme celui des prothèses mammaires PIP, il était devenu urgent, au niveau européen, de réviser les règles en vigueur en matière de dispositifs médicaux. C’est pourquoi je me suis exprimée en faveur de ce rapport afin d’éviter que nous ayons à connaître de nouveaux drames qui mettent gravement en danger la santé des citoyens. Malgré un intense lobbying industriel, j’ai soutenu l’introduction d’une autorisation de mise sur le marché pour les dispositifs médicaux implantables à haut risque. Ces produits à haut risque implantés dans le corps ne devraient obtenir de marquage CE qu’à des conditions strictes.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-234-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28117.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jim Higgins (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I welcome the referral of this report back to committee. Innovation, consumer protection and the protection of EU jobs all need to be balanced. Like the in vitro devices regulation this directive also aims to address inconsistencies in Member Statesʼ interpretation of current rules, thus increasing the protection of public health and safety, removing obstacles to the internal market, etc. And similarly to my explanation of vote on the Liese Report I would like to voice concerns concerning the prescriptive nature of the report and the need to ensure that life-saving devices make it to the market as quickly as is safely possible. We cannot allow bureaucracy to slow down medical progress. I welcome the rejection by the Committee on the Environment, Public Health and Food Safety of the ‘preliminary marketing authorisationʼ as that would hinder the speed of medical progression; it would also cost the EU its innovative edge on the world market. I also welcome the increased level of transparency that this directive will ensure, as this will help to combat the counterfeit manufacturer of such products.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-235-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96693.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Juozas Imbrasas (EFD), </span></span>  <span class="italic">raštu</span><span class="bold">. − </span>Balsavau už medicinos prietaisų taisyklių pataisas, kuriomis siekiama sustiprinti šių gaminių, pavyzdžiui, krūtų implantų ar klubo sąnarių protezų, kontrolę ir atsekamumą. Europos Parlamento pasiūlytos medicinos prietaisų naudojimo taisyklių pataisos leis pacientams ir sveikatos apsaugos specialistams lengviau prieiti prie klinikinių duomenų, kurie padėtų parinkti tinkamiausią medicinos prietaisą gydymui. Atsižvelgdami į neseniai kilusius skandalus dėl brokuotų krūtų implantų ir klubo sąnario protezų, EP nariai siūlo įvesti implantų registracijos korteles, kurios leistų atsekti juos turinčius pacientus ir kuo skubiau juos informuoti apie galimą jiems implantuoto prietaiso defektą. Labai svarbu tinkamai informuoti pacientus apie genetinių tyrimų pasekmes, numatyti medicinos prietaisus sertifikuojančias įstaigas ir padidintų šių prietaisų atsekamumą.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-235-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119875.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Iñaki Irazabalbeitia Fernández (Verts/ALE), </span></span>  <span class="italic">por escrito</span><span class="bold">. − </span>He votado a favor del informe ya que supone un paso adelante en la protección de la ciudadanía frente a abusos y fraudes en este ámbito, como el de los implantes de silicona defectuosos. El texto aprobado tiene, sin embargo, lagunas y partes mejorables como es la referida a evaluación de la seguridad de los nanomateriales.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-235-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96884.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Philippe Juvin (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai voté en faveur du rapport de ma collègue Dagmar Roth-Behrendt, qui pose des règles importantes sur le contrôle des dispositifs médicaux après leur entrée sur le marché ainsi que sur les organismes notifiés chargés d'effectuer ces contrôles. Ces règles empêcheront qu'une nouvelle fraude comme celle effectuée par la société PIP se produise en Europe. Je me félicite de l'adoption de ce texte.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-236-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102887.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Béla Kovács (NI), </span></span>  <span class="italic">írásban </span><span class="bold">− </span>Sokkal kevesebb orvostechnikai berendezésre volna szükség hazánkban, ha tisztességes kormányzati tevékenység révén normális lakhatási, élet- és munkakörülmények volnának biztosíthatók lényegében minden dolgozni vágyó hazánkfia számára. Sajnos erre utaló törekvést csak a szavak szintjén tapasztalok, tettekben inkább az ellenkezője történik. Az adott jelentés az orvostechnikai eszközök jelenlegi szabályozási keretének felülvizsgálatára irányuló bizottsági javaslatot tárgyalja. Az előadó szerint a javaslat gyenge pontja, hogy a szöveg szerkezetének jobban kellene tükröznie az eszközök életciklusának logikai felépítését. Ezenkívül kiemeli az átláthatóság hiányát, szorgalmazza az orvostechnikai eszközök értékelésével foglalkozó bizottságot (ACMD), valamint az egyszer használatos és újrafelhasználható címkék egyértelmű szabályozását. Szakmailag a módosítókkal a javaslat elfogadható és előrelépést jelent a jelenlegi állapothoz képest, így azt támogattam. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-236-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96816.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Giovanni La Via (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>La sicurezza in ambito sanitario è un principio fondamentale di cui dobbiamo farci portatori per assicurare un’assistenza sanitaria adeguata e che punti a ridurre i casi di mala sanità derivanti dall’utilizzo di dispositivi medici non sempre adeguati. Pertanto, ho espresso voto favorevole alla presente relazione poiché ritengo che essa, insieme a quella relativa ai dispositivi medici in vitro, mantenga fermo il correlato approccio orizzontale tra le due materie e, al tempo stesso ne distingua gli ambiti di applicazione, ove opportuno. Una maggiore sicurezza ed uniformità nell’ambito dell’utilizzo dei dispositivi medici e delle relative autorizzazioni rappresenta un buon viatico per proseguire nella strada positiva, segnata dalle indicazioni contenute nella presente relazione.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-236-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/105849.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Agnès Le Brun (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Les dispositifs médicaux sont des instruments ou appareils qui visent à atténuer une maladie ou à compenser un handicap sans moyens pharmacologiques. Ils représentent environ un demi-million de produits différents, des bandages adhésifs aux appareillages à rayon X. Les 25 000 entreprises européennes de technologies médicales emploient plus d'un demi-million de personnes et ont déposé plus de 10 000 demandes de brevets en 2012. Face à la multiplication des incidents, tels que le scandale des prothèses PIP, le Parlement européen a révisé la législation existante. J'ai voté en faveur de ce texte car il améliore l'information et la protection de la santé des patients, ainsi que la traçabilité des dispositifs médicaux, sans entraver l'innovation. Nous avons étendu la législation aux dispositifs esthétiques (implants, lentilles à visée esthétique). Nous avons également renforcé les contrôles. Ainsi, les organismes de certification pourront désormais mener des inspections inopinées chez les fabricants, une base de données européenne permettra de signaler tout incident et un groupe d'experts européens sera chargé de coordonner les mesures nationales en cas de problème. Les dispositifs à risque innovants ou ayant provoqué des incidents par le passé devront être autorisés par des experts européens indépendants avant d'être mis sur le marché.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-237-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23768.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Bogusław Liberadzki (S&amp;D), </span></span>  <span class="italic">na piśmie</span><span class="bold">. − </span>Głosowaliśmy dzisiaj nad projektem w sprawie wniosku dotyczącego rozporządzenia Parlamentu Europejskiego i Rady w sprawie wyrobów medycznych, zmieniającego dyrektywę 2001/83/WE, rozporządzenie (WE) nr 178/2002 i rozporządzenie (WE) nr 1223/2009. Rozporządzenie to ma na celu zapewnienie funkcjonowania rynku wewnętrznego w obszarze wyrobów medycznych, uwzględniając jako podstawę wysoki poziom ochrony zdrowia pacjentów, użytkowników i osób obsługujących dane wyroby. Jednocześnie rozporządzeniem tym ustanawia się wysokie normy jakości i bezpieczeństwa wyrobów medycznych w odpowiedzi na powszechne obawy w tym zakresie. Do osiągnięcia obu tych celów dąży się jednocześnie. Są one nierozerwalne i żaden z nich nie jest podrzędny wobec drugiego. Pragnienie zapewnienia pacjentom łatwego dostępu do nowych wyrobów medycznych nigdy nie powinno być ważniejsze od potrzeby zapewnienia bezpieczeństwa pacjentów. Odnosząc się do pierwszej zasady Hipokratesa, zgodnie z którą pracownicy służby zdrowia mają przede wszystkim obowiązek nie szkodzić, poprawki, które dzisiaj przegłosowaliśmy, ułatwią publiczny dostęp do danych klinicznych zarówno profesjonalistom, jak i obywatelom, aby wiedzieli, jakiego produktu powinni użyć. Mowa o produktach, które mają ulżyć pacjentom w cierpieniu i chorobie. Powinniśmy pomagać obywatelom UE, jak również lekarzom, w dostępie do najlepszych produktów, dlatego opowiedziałem się za przyjęciem rozporządzenia.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-237-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/1403.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">David Martin (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I voted in favour of this report because we need tougher regulation of medical devices. When there have been scandals of defect products on the market, many patients are often left feeling vulnerable because of the lack of a traceability system. This is not acceptable.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-238-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23704.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jiří Maštálka (GUE/NGL), </span></span>  <span class="italic">písemně</span><span class="bold">. − </span>Sektor kontroly bezpečnosti zdravotnických prostředků představuje další část naplnění jednoho z pilířů společné evropské politiky, tj. zajištění bezpečnosti pro spotřebitele. Po dlouhou dobu zůstávaly zdravotnické prostředky nepokryty. K vytvoření předloženého dokumentu mimo jiné vedly alarmující případy, jako vadné prsní implantáty. Předkládaný návrh jednak svým obsahem rozděluje zdravotnické prostředky do rizikových tříd a svým obsahem pokrývá i zdravotnické prostředky, které byly vyvinuty díky novým technologiím. Odpovědí na nové požadavky je vznik evropské databanky, která bude vést přesný přehled o povolených, certifikovaných zdravotnických prostředcích. Nařízení neporušuje princip subsidiarity, protože odpovědnost za vkládání údajů nesou jednotlivé členské státy. Velmi pozitivním prvkem je, že Komise a členské státy musí zajistit realizaci práva na informace a přístup k nim. Nařízení jako celek je příspěvkem k podpoře bezpečnosti pacientů a navrácení jejich důvěry ve zdravotní prostředky Evropské unie.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-238-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4462.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Clemente Mastella (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Risulta essenziale procedere alla revisione del quadro legislativo europeo in materia di dispositivi medici, perché riteniamo sia indispensabile un suo miglioramento per la tutela della salute pubblica e dei pazienti europei. </p>
<p class="contents">Appoggiamo quindi questa proposta di relazione volta a rinforzare ulteriormente il quadro normativo esistente. È necessario sottoporre i dispositivi medici potenzialmente più rischiosi per i pazienti, come quelli impiantati nel corpo contenenti una sostanza medicinale o che utilizzano tessuti umani o animali, a procedure sempre più rigorose. Al comitato di valutazione di tali dispositivi, composto dai migliori specialisti, andrà affiancata una rappresentanza sia di pazienti sia di esperti dell'Agenzia europea per i medicinali. </p>
<p class="contents">Siamo concordi, inoltre, sul rafforzamento del personale delle autorità nazionali, affinché siano sempre più competenti, sulla necessità che i fabbricanti di medicinali abbiano la possibilità di presentare domanda ad un organismo notificato in altro Stato membro rispetto a quello di registrazione e chiediamo, inoltre, che le indagini cliniche inizino solo previo ottenimento di una valutazione positiva da parte di un comitato etico indipendente. </p>
<p class="contents">Sarà infine fondamentale avere sempre un occhio di riguardo nei confronti delle erogazioni economiche allo scopo di evitare inutili sprechi. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-238-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4412.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Véronique Mathieu Houillon (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai voté en faveur du rapport sur les dispositifs médicaux afin d'améliorer la sécurité des patients européens. Les textes en vigueur, bien que révisés en 2007, sont dépassés par les progrès technologiques et scientifiques. Par ailleurs, l'actualité liée aux implants mammaires et aux prothèses de la hanche défectueux a mis en lumière la nécessité de renforcer l'évaluation de la conformité des dispositifs, d'améliorer la transparence et l'accès aux informations par les professionnels de la santé et les patients, ainsi que de renforcer la traçabilité : ce qui sera mis en œuvre grâce au vote de ce texte. Ce règlement couvre de nombreux produits tels que les pansements, les verres optiques, les lentilles de contact, les stimulateurs cardiaques, les tests de grossesse, les implants mammaires, etc.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Ce règlement a le mérite de préciser les normes encadrant les dispositifs médicaux. On note un durcissement des dispositions contre la fraude. Les États membres sont invités à prévoir des sanctions sévères et à les appliquer. Les "dispositif à visée esthétique" sont ajoutés dans le champ de la réglementation. Le rapport interdit les mentions pouvant induire en erreur et appelle au respect du principe du consentement libre et éclairé. Encore une fois le rapport ne s'intéresse pas à la question cruciale des conditions sociales et écologiques de production de ces dispositifs médicaux. En l'absence d'une telle harmonisation sociale, la libre circulation des dispositifs médicaux favorise la délocalisation des fabricants. La France est largement concernée : elle importe déjà 55 % des dispositifs médicaux qu'elle consomme. Pourtant sa capacité de production continue de décliner, en dépit de ses capacités productives et intellectuelles. Je vote pour ces avancées normatives. Mais je déplore une nouvelle étape de la libéralisation du marché au détriment des travailleurs et de l'objectif de relocalisation des productions.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-625"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96978.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Melo (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Os dispositivos médicos, como implantes mamários, <span class="italic">pacemakers</span> e próteses da anca, deverão ser submetidos a uma avaliação de segurança mais apertada em toda a UE, de acordo com o aprovado no presente relatório. As normas propostas visam também melhorar a rastreabilidade para permitir, por exemplo, uma retirada rápida dos dispositivos do mercado europeu. Os dispositivos médicos abrangem uma vasta gama de produtos, desde artigos de utilização doméstica como pensos rápidos, lentes de contacto, a produtos para obturação dentária, máquinas de raios X, <span class="italic">pacemakers</span>, implantes mamários, próteses da anca, etc. Existem no mercado milhares de tipos diferentes de dispositivos, classificados em diferentes categorias de risco. Acontecimentos recentes, como o escândalo sobre os implantes mamários fraudulentos em silicone e os problemas causados por certas próteses da anca de metal sobre metal, trouxeram estas questões à atenção do público. Com estas novas regras pretende-se reforçar os controlos de segurança dos dispositivos médicos, assegurando uma melhor rastreabilidade dos mesmos e fortalecendo a supervisão dos organismos de certificação por parte das autoridades nacionais, tendo em vista garantir a segurança dos pacientes. Daí o meu voto favorável.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-718"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28407.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Willy Meyer (GUE/NGL), </span></span>  <span class="italic">por escrito</span><span class="bold">. − </span>He votado a favor del presente informe debido a que supone una mejora en la reglamentación de los productos sanitarios. La industria farmacéutica es uno de los sectores más pujantes a nivel internacional y en numerosos ocasiones desarrolla productos que suponen riesgos para la salud pública. Así lo demuestran numerosos escándalos de contaminación, enfermedades e incluso muertes por la introducción en el mercado de productos que ponían en riesgo la vida de los consumidores de este tipo de productos. El informe propone una regulación más restrictiva; solo a través de un mayor control público de estos productos se puede reducir los riesgos para la salud a los que estas empresas exponen a la población. Por ello he votado a favor del presente informe.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-239-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28178.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Miroslav Mikolášik (PPE), </span></span>  <span class="italic">písomne</span><span class="bold">. − </span>Vítam túto potrebnú revíziu legislatívy s dôrazom na zlepšenie prístupu k zdravotníckym pomôckam, ale najmä ich bezpečnosť pre pacientov. Práve bezpečnosť je kľúčovým bodom v procese ich schvaľovania na základe dostatočných klinických skúšok. Zvlášť prísnym kritériám musia podliehať tie pomôcky, ktoré sú určené na implantovanie do tela, čo sa zabezpečí vytvorením osobitných notifikovaných subjektov pre posudzovanie zhody. Takéto subjekty musia fungovať efektívne, transparentne a kvalifikovane. Chcem podčiarknuť význam nezávislej etickej komisie, ktorá musí vydať posudok ešte pred začatím klinického skúšania tak, ako je tomu aj v prípade klinických štúdií na lieky. Všetky členské štáty musia zabezpečiť riadne fungovanie takýchto komisií.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-239-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96999.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alexander Mirsky (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>Medical devices are instruments, software or implants which are used for diagnosis, monitoring, treatment or replacement due to injury or disability. They cover a huge spectrum of products ranging from low-risk products such as corrective glasses, sticking plasters, etc. to high risk products such as pacemakers, hip implants, etc. I voted in favour, because the existing regulatory framework for medical devices dates back to 1990 and 1993 and needs to be updated substantially.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96930.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vital Moreira (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Votei a favor do relatório Roth-Behrendt acerca da proposta de regulamento sobre dispositivos médicos, porém, com as mesmas reservas que sempre tenho em votar instrumentos legislativos tão longos e tão técnicos, sem poder avaliar devidamente o seu impacto. Em primeiro lugar, trata-se de uma matéria que, em grande parte, se reveste de uma natureza técnico-regulamentar que não devia figurar num instrumento legislativo do Parlamento. Cabe perguntar se não se justificaria utilizar mais generosamente a possibilidade de delegação de poderes regulamentares à Comissão. Em segundo lugar, penso que a emissão unilateral de instrumentos regulatórios sobre dispositivos médicos pode acentuar a divergência regulatória entre a União e os nossos principais parceiros económicos, aumentando as barreiras ao comércio internacional. No momento em que a União negoceia com os EUA um ambicioso tratado de comércio e investimento, incluindo a aproximação de padrões regulatórios, julgo que instrumentos legislativos como estes deveriam ser submetidos a uma avaliação de impacto sobre as suas implicações no comércio internacional da União e ser também objeto de consulta prévia no quadro do diálogo regulatório com os EUA e com outros importantes parceiros comerciais da União.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-468"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96760.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tiziano Motti (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>La presente proposta è oggi adottata parallelamente a una proposta di regolamento sui dispositivi medico-diagnostici in vitro (IVD), come i test ematici, che sono disciplinati dalla direttiva 98/79/CE del Parlamento europeo e del Consiglio. Gli aspetti orizzontali comuni a entrambi i settori sono stati armonizzati, mentre le caratteristiche specifiche di ciascun settore richiedono ragionevolmente atti giuridici distinti. L'attuale quadro normativo ha dimostrato i propri meriti, ma è anche stato oggetto di dure critiche, in particolare quando le autorità sanitarie francesi hanno accertato che un fabbricante francese (Poly Implant Prothèse, PIP) per diversi anni ha apparentemente utilizzato silicone industriale anziché silicone di grado medico per la produzione di protesi mammarie, in violazione dell'autorizzazione rilasciata dall'organismo notificato, danneggiando la salute di migliaia di donne nel mondo. Mi rallegro quindi che oggi si sia presa una posizione di contrasto a future simile pratiche. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96783.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Wojciech Michał Olejniczak (S&amp;D), </span></span>  <span class="italic">na piśmie</span><span class="bold">. − </span>Bezpieczne i innowacyjne wyroby medyczne są niezwykle ważne dla pacjentów, lekarzy i przemysłu technologii medycznej. Obejmują one szeroki zakres różnych produktów, od plastrów, przez testy ciążowe, soczewki kontaktowe i urządzenia rentgenowskie, po rozruszniki serca i testy na obecność HIV. Nowe rozporządzenia dotyczące wyrobów medycznych zaproponowane przez Komisję Europejską są istotne, ponieważ mają na celu polepszenie nadzoru rynku, wzmocnienie pozycji jednostek notyfikowanych oraz zapewnienie przejrzystości identyfikowalności produktów. Wierzę, że te rozporządzenia pomogą w uniknięciu takich sytuacji, w których ujawniono wszczepienie wadliwych implantów piersi, które zawierały tani, przemysłowy silikon i które były dostępne na rynku przez ponad dziesięć lat, oraz uniknięcia katastrof związanych z implantami biodra, stentów wewnątrzczaszkowych etc. W celu zapewnienia lepszej oceny skuteczności oraz bezpieczeństwa wyrobów medycznych o wysokim stopniu ryzyka, zanim zostaną one wprowadzone do obrotu, niezbędne jest wprowadzenie ulepszeń Parlamentu Europejskiego. Mając na uwadze poprawę bezpieczeństwa pacjentów i ochronę zdrowia publicznego, całkowicie popieram wniosek o wprowadzenie nowych przepisów, wraz z poprawkami ze sprawozdania Pani Roth-Behrendt.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/26829.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Siiri Oviir (ALDE), </span></span>  <span class="italic">kirjalikult</span><span class="bold">. − </span>Arvestades asjaolu, et olemasolev meditsiiniseadmeid käsitlev õiguslik raamistik on juba kakskümmend aastat vana ja selles valdkonnas on toimunud palju muutusi, toetasin raportit, mille eesmärk on patsientide turvalisuse tagamine ning selleks vastavate muudatuste sisseviimine. </p>
<p class="contents">Üks olulisem muudatus, mis peaks tulevikus patsientide turvatunde tagama, on nn implantaadi kaardi süsteemi kehtestamine, millega patsiendid ja arstid saaksid ligipääsu turul olevate seadmete andmetele, et valida välja sobivaim ehk kvaliteetne ja ohutuim lahendus. Patsientide turvalisuse tagamiseks on oluline ka see, et ühekordseks kasutamiseks mõeldud meditsiiniseadmeid ei tarvitataks korduvalt, mistõttu on hädavajalik seadet taaskasutavale isikule või asutusele tagajärgede eest vastutuse panemine. Võimalus raviasutustes nakatuda või saada tüsistus hooletu ja n-ö kokkuhoidliku suhtumise tõttu on lubamatu. Nimetatud suhtumine ja praktika läheb meie ühiskonnale hiljem kordades rohkem maksma.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-812"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28279.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Justas Vincas Paleckis (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I voted in favour of this report on medical devices, because the current regulation is 20 years old and outdated, and improvements are necessary. Stronger supervision of notified bodies (which approve medical devices), unannounced checks on manufacturers, a database on medical devices for better public information, and improvements in safety concerns through a unique identifier which will provide better traceability and recall information, are needed. I support the Socialist MEP Roth-Behrendt’s report, because it also focuses on strengthening the patient-safety side of the legislation through a pre-marketing process for high-risk devices, strengthening requirements for notified bodies by increasing expertise and making it available in-house, and creating stricter conditions for multi-use medical devices. With the additions in this report, patient safety and public health would become the main focus when it comes to medical devices.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-240-875"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97197.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alfredo Pallone (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Da anni si sentiva il bisogno di modificare e modernizzare la regolamentazione esistente in materia di dispositivi medici. </p>
<p class="contents">Ho votato a favore della modifica della direttiva perché gli scandali degli ultimi anni hanno minacciato la sicurezza e la salute dei pazienti che ora, con questo nuovo regolamento, saranno garantiti sulla certezza dei prodotti, sulla produzione e sicurezza dei vari dispositivi medici. Inoltre, con l'avanzare della tecnologia, si è ritenuto necessario adattare il tessuto normativo ai nuovi macchinari andando quindi, oltre che a tutelare e garantire il paziente, ad incentivare l'innovazione e la produzione dei dispositivi medici.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-241-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97050.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Antigoni Papadopoulou (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>Since medical devices cover a huge spectrum of products used for diagnosis, monitoring, treatment or replacement following injury or disability, the present regulatory framework needs updating to be fully in line with technological and scientific advances. The current rules are interpreted and implemented in different ways by EU Member States, which puts patients’ safety and health protection at risk. The Commission underlines that all notified bodies need stronger supervision owing to insufficient transparency; manufactures need stricter controls; the public requires more information concerning medical devices; and unique monitoring systems must be in place to trace and recall any malfunctioning devices. As parliamentarians, we strongly believe that a more centralised pre-marketing authoritarian procedure for high risk devices is needed, as well as reinforcement of the qualifications of the staff of the notified bodies and stricter terms of implementation of multiple use devices. Devices labelled as single-use should be used only for single-use and not reprocessed. Despite different approaches towards the framework, we should keep in mind that the safety and protection of patients from defective medical devices should be guaranteed. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-241-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96902.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria do Céu Patrão Neves (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Votei favoravelmente o presente relatório que estabelece regras mais apertadas de avaliação de segurança para os dispositivos médicos. As normas hoje aprovadas pelo Parlamento Europeu visam igualmente melhorar a rastreabilidade dos DM para que, por exemplo, no caso de defeito/risco se possa rapidamente identificar os seus portadores e/ou serem retirados do mercado com a celeridade exigida. Estas novas normas procuram ainda fortalecer a supervisão dos organismos de certificação por parte das autoridades nacionais, tendo em vista garantir a segurança dos pacientes. Os organismos de certificação, que recorrem frequentemente a subcontratantes, deverão, no futuro, dispor de pessoal científico permanente com experiência e formação suficientes para avaliar a funcionalidade médica dos dispositivos. Os pacientes deverão receber um <span class="italic">cartão de implante</span>, de modo a poderem ser identificados e alertados no caso de se registarem incidentes com produtos similares.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-241-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36392.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Aldo Patriciello (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>The proposal for a regulation on medical devices and active implantable medical devices attempts to regulate the standards of safety, quality and efficiency of medical devices which affect citizens of the European Union. Different types of medical devices currently on the market in the European Union, such as syringes and blood sampling devices, should be required by law to be safe not only for patients but also for the healthcare professionals who handle them. Since these points are specified under this proposed regulation, I voted in favour of it.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-241-750"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23693.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Alojz Peterle (PPE), </span></span>  <span class="italic">pisno</span><span class="bold">. − </span>Sprejeli smo predlog predpisov za strožje spremljanje in postopke certificiranja medicinskih pripomočkov, s katerimi želimo zagotoviti njihovo polno skladnost in sledljivost. Predlog tudi poostri zahteve po več informacijah in višjih etičnih zahtevah za diagnostične medicinske pripomočke, ki se uporabljajo na primer v nosečnosti ali testiranju DNK. Predlagana zakonodaja lahko izboljša preglednost informacij za paciente in zdravstvene delavce ter okrepi predpise o sledljivosti, hkrati pa ne ustvarja dodatna bremena za inovativne majhne proizvajalce. Spremembe bi zdravnikom in pacientom omogočile dostop do podatkov s kliničnih testiranj, da bi se lažje odločili, kateri medicinski izdelek naj uporabijo. Podpiram predloge, ki dajo pacienta v središče.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-242-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28409.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Raül Romeva i Rueda (Verts/ALE), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>In favour. Implantable devices are not like medicines: when a serious incident occurs, it is not possible to just stop the treatment – the patient has to be operated on again. The recent scandals with faulty breast implants, hip replacements and other devices have underlined serious flaws in EU legislation on medical devices. The Greens/EFA supported the rapporteur, who pushed for a pre-market approval, but EPP, ALDE and ECR were strictly against. Faced with this political reality, we supported the stronger controls so as to have a better evaluation of high-risk devices before they are put on the market. We succeeded in getting our proposal that innovative high-risk devices should always be assessed against the existing reference treatment adopted. Both of these provisions are crucial for ensuring that such devices are safe for public health and actually represent added therapeutic value. We were the driving force for restrictions of hazardous substances. However, the text adopted in ENVI is not consistent (scope of medical devices covered unnecessarily wide, phase-out time too long, very narrow definition of endocrine disrupters). </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-242-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96746.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marie-Thérèse Sanchez-Schmid (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai voté en faveur de ce rapport qui permet un renforcement des contrôles sur les dispositifs médicaux comme les implants mammaires ou prothèses de hanche. Ces mesures visent notamment à tirer les leçons du scandale des implants mammaires défectueux de la société française PIP. On estime à 500 000 le nombre de femmes portant des prothèses PIP dans le monde, sans disposer d'outils de prévention, de traçabilité et d'identification des potentielles victimes. Le texte adopté vise à harmoniser l'interprétation des règles actuelles, à protéger davantage la santé publique, à encadrer l'évaluation du risque des dispositifs médicaux, à améliorer la transparence des informations données aux patients et à renforcer les règles de traçabilité.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-242-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4423.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Amalia Sartori (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Il settore dei dispositivi medici occupa oltre mezzo milione di dipendenti e conta un mercato di cento miliardi di euro. Le aziende europee che vi operano sono principalmente piccole e medie imprese portatrici di innovazione nel settore, con più di diecimila domande di brevetto nel 2012. Ho votato a favore della presente relazione nella convinzione che sia necessario modernizzare la legislazione nel settore dei dispositivi medici per garantire maggiore sicurezza, trasparenza e tracciabilità, ma con alcuni importanti emendamenti rispetto alla posizione contenuta nella relazione della on. Roth-Behrendt. In particolare, sono contraria all’introduzione di un doppio livello di certificazione dei dispositivi medici: un primo controllo da parte degli organismi notificati e un secondo da parte di un Comitato di valutazione. Ciò burocratizzerebbe eccessivamente la procedura, che si prolungherebbe oltre la vita media dei prodotti stessi, con costi non sostenibili per le PMI, che costituiscono la maggioranza delle aziende operanti nel settore. Inoltre, in merito al riutilizzo dei dispositivi monouso, ritengo che i costi relativi ad un corretto ricondizionamento non siano tali da giustificare la posizione secondo cui rappresenterebbero un risparmio significativo per gli ospedali. Supporto, invece, la scelta di introdurre maggiori controlli sugli organismi notificati e la possibilità di acceso da parte di esperti clinici durante la valutazione.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-243-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/28223.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Andreas Schwab (PPE), </span></span>  <span class="italic">schriftlich</span>. <span class="bold">− </span>Nach den Vorfällen um Brustimplantate, die mit minderwertigem Industriesilikon gefüllt waren, begrüße ich die Neufassung der Medizinprodukte-Richtlinie. Auch wenn es sich dabei um einen Einzelfall mit kriminellem Hintergrund gehandelt hat, bleibt das Ziel einer europaweit einheitlichen Medizinprodukte-Regelung ein erstrebenswertes Ziel. Im Rahmen dieses Gesetzgebungsprozesses waren gefährliche Vorschläge eingebracht worden, die für viele kleine und mittelständische Unternehmen das „Aus“ bedeutet hätten. Diese Vorschläge sind mit der heutigen Abstimmung vom Tisch. Allerdings habe ich dennoch heute gegen den Entwurf in der vorliegenden Form gestimmt. Denn die ursprünglich angedachte zentrale Zulassung von Medizinprodukten ist ersatzlos gestrichen worden. Leider konnte der Anwendungsbereich des Zulassungsverfahrens und zusätzlichen Bewertungsverfahrens heute nicht so eingeschränkt werden, wie dies geplant war: Denn bei einem zu breiten Anwendungsbereich von Medizinprodukten und richtigerweise aber enger Kriterien für die Einleitung des Verfahrens kann nun eine Prüfung eines neuen Medizinprodukts herbeigeführt werden. Zwar konnten wir erreichen, dass die zusätzlichen Kosten dieses Bewertungsverfahrens nicht dem betroffenen Unternehmen auferlegt werden, jedoch ist damit der Schutz der Patienten zwar an der richtigen Stelle verbessert, die Innovationsfähigkeit der Medizinproduktehersteller aber einem Risiko ausgesetzt. Und das hilft am Ende auch den Patienten nicht im geringsten.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-244-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96718.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Olga Sehnalová (S&amp;D), </span></span>  <span class="italic">písemně</span><span class="bold">. − </span>Podpořila jsem návrh nařízení o zdravotnických prostředcích, neboť nedávné zdravotnické skandály v Evropě bolestivě ukázaly, že systém schvalování zdravotnických prostředků má závažné trhliny. Aktualizace stávajících pravidel je proto nutná nejen kvůli těmto skandálům, ale také kvůli značnému technologickému pokroku. Vítám, že návrh zavádí například přísnější bezpečnostní kontroly, posiluje účinnější dohled nad trhem a zaručí lepší přístup k informacím pro veřejnost. Za konkrétní zlepšení pro spotřebitele považuji opatření k zavedení povinných neohlášených namátkových kontrol výrobců, což přispěje k vyšší transparentnosti, a také částečné zpřístupnění databáze zdravotnických prostředků Eudamed. Pacienti budou mít konečně možnost informovat se o provedených klinických testech a certifikátech zdravotnického prostředku, který je jim implantován. Jsem naopak proti opakovanému používání zdravotnického materiálu určeného pro jedno použití, které může ohrozit bezpečnost a zdraví pacientů.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-244-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. − </span>Accolgo positivamente la proposta della Commissione finalizzata alla revisione del quadro normativo esistente in materia di dispositivi medici. Si tratta della revisione di un quadro legislativo esistente da vent'anni che era particolarmente necessaria. In generale, concordo con i miglioramenti apportati dalla Commissione in termini di classificazione dei dispositivi medici in quattro classi secondo il livello di rischio che presentano per i pazienti. Negli ultimi anni la procedura di valutazione della conformità ha mostrato notevoli lacune, come la mancanza di trasparenza, la rapida approvazione e immissione sul mercato di dispositivi medici in assenza di adeguate indagini su pazienti e quindi di sufficienti dati clinici, con conseguenti rischi per i pazienti. Ritengo che sia necessario sottoporre i dispositivi medici potenzialmente più rischiosi per i pazienti a procedure più rigorose di quelle di una valutazione della conformità, bene quindi l'istituzione di un comitato di valutazione per i dispositivi medici (ACMD) che si occupi della valutazione caso per caso, laddove i suoi membri abbiano ritenuto necessario chiedere l'esame dei dati clinici. L'etichettatura dei dispositivi come monouso (o riutilizzabili) va rivista, in quanto ritengo che i dispositivi etichettati come monouso debbano essere realmente monouso e che le opzioni debbano essere soltanto due: monouso o riutilizzabile.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-245-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96655.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Monika Smolková (S&amp;D), </span></span>  <span class="italic">písomne</span><span class="bold">. − </span>Podobne ako v prípade správy diagnostických zdravotníckych pomôcok in vitro som hlasovala aj za túto správu, pretože ju považujem za dôležitú súčasť bezpečnosti, kvality a efektivity zdravotníckych pomôcok, ktorých cieľom je riešiť bezpečnostné obavy v súvislosti s týmito výrobkami. Aj keď by mohli byť do nového regulačného rámca zapracované aj niektoré ďalšie zmeny a opatrenia, som rada, že Komisia prichádza s riešením klasifikácie zdravotných pomôcok, ktoré zaraďuje do štyroch kategórii podľa miery rizika pre pacientov. Myslím si, že tieto zmeny môžu pomôcť pri odstraňovaní závažných nedostatkov, ktoré sa v minulosti objavovali. Očakávam, že zdravotnícke pomôcky, ktoré predstavujú pre pacientov najväčšie riziká, budú podliehať prísnejším postupom a nie len posudzovaniu zhody notifikovanými orgánmi. Za veľmi znepokojujúcu informáciu považujem to, že fungovanie notifikovaných orgánov sa za posledné obdobie hodnotí ako veľmi slabé. Svedčia o tom zásadne rozdiely vykonaných hodnotení zhody, nedostatočná transparentnosť týchto organizácii, ich prebujnenosť a pod. Som presvedčená, že v záujme zlepšenia tejto situácie dôjde na národných úrovniach k posilneniu ustanovení týkajúcich sa personálneho obsadenia notifikovaných subjektov. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-246-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4545.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Catherine Stihler (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>I support the Medical Devices Regulation because I am in favour of tougher regulation of medical devices rather than supporting industry.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-247-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96920.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kay Swinburne (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>This proposal for a regulation on medical devices is a very important one, and one on which we must deliver smart legislation that reflects the needs of patients across the EU. I hope that, following this vote today, negotiations on this proposal with Member State Governments can deliver such proportionate regulation with patient safety at its core.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-248-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>La Commission propose de combler les lacunes de la législation régissant actuellement les dispositifs médicaux: renforcement de la supervision des organismes notifiés afin de garantir la conformité de l’évaluation; renforcement du contrôle des producteurs au moyen d’inspections non annoncées; amélioration de l’information publique par l'extension de la base de données des dispositifs médicaux; instauration d’un identifiant unique pour améliorer la traçabilité et les rappels en cas de soucis de sécurité. Alors que la rapporteure salue les efforts de la Commission, elle regrette la fixation excessive sur la promptitude de la commercialisation des dispositifs médicaux, au détriment de la sécurité des patients. Le rapport de Dagmar Roth-Behrendt a pour but de renforcer les aspects de la législation touchant à la sécurité des patients. À cet effet, il propose la mise en place d’une procédure d’autorisation centralisée de précommercialisation, applicable aux dispositifs à haut risque, impliquant une agence publique de la santé à l’échelle de l’UE (AEM), le renforcement des critères de qualification du personnel des organismes notifiés et la présence d’une expertise maison, et le renforcement des critères régissant les dispositifs à usage multiple, fondé sur des normes de retraitement applicables à l'échelle de l'Union. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-248-250"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96974.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nuno Teixeira (PPE), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>A proposta de regulamento revoga a directiva actualmente em vigor, alargando e clarificando o âmbito de aplicação, alinhando as definições pelas práticas internacionais, bem como através de regras mais exigentes sobre a avaliação e a investigação clínicas. O documento visa questões como a classificação dos dispositivos, o sistema de aprovação dos dispositivos médicos, a rotulagem dos dispositivos como dispositivos de uso único (ou reutilizáveis) e reprocessamento de dispositivos, as investigações clínicas, a utilização do Banco de Dados Europeu sobre Dispositivos Médicos (EUDAMED), a vigilância e fiscalização do mercado e a coordenação entre os Estados-Membros e o Grupo de Coordenação dos Dispositivos Médicos. Tendo em consideração estes vários pontos, votei a favor do documento.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-248-312"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/114279.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Isabelle Thomas (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>Le scandale sur les prothèses mammaires PIP et le manque de vigilance mis en lumière par l'affaire des prothèses de hanche "métal contre métal" ont amené les parlementaires à faire pression sur la Commission européenne pour qu'elle révise les directives ayant trait aux dispositifs médicaux. Les négociations ont été rudes, et j'aurais souhaité que les dispositifs médicaux les plus à risque soient systématiquement et préalablement évalués au travers d’une expertise collégiale indépendante. Mais, parce que la mise en place d'un nouveau groupe d'organismes désigné par l'Agence européenne du médicament qui évaluera au préalable les dispositifs considérés comme à haut risque représente tout de même une avancée pour la sécurité des patients, j'ai soutenu ce rapport. Concernant les dispositifs à usage unique, c’est pour réglementer les pratiques de retraitement devenues trop courante en Europe qu'il était devenu urgent de l'aborder au sein d’une législation européenne. Les dispositifs à usage unique seront listés et il sera possible après une évaluation scientifique de retirer un dispositif de cette liste afin que son retraitement soit autorisé. Néanmoins, la possibilité pour les États membres d'interdire le retraitement des dispositifs médicaux à usage unique a été maintenu.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-248-375"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marie-Christine Vergiat (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. – </span>J'ai voté en faveur de ce rapport relatif aux dispositifs médicaux. Par "dispositif médical" on entend l'ensemble des instruments de soins de santé, des simples pansements aux outils plus complexes tels que les stimulateurs cardiaques, les remplacements de la hanche et les implants mammaires. Après une série de révélations liées à la santé, notamment l'affaire PIP et le scandale des prothèses de hanche, nous nous devions au sein du groupe de la GUE d'être particulièrement vigilants. Ce rapport législatif, s'il est validé par le Conseil, mènera à plus grande transparence du processus d'accréditation des dispositifs médicaux, un meilleur contrôle des organismes notifiés et à un meilleur contrôle des sous-traitants et filiales. La responsabilité du fabricant sera également accrue : avant de placer un dispositif médical sur le marché, les fabricants devront s'assurer qu'ils sont couverts par une assurance responsabilité civile appropriée couvrant le risque d'insolvabilité et des dommages aux patients.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-248-500"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97016.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Angelika Werthmann (ALDE), </span></span>  <span class="italic">schriftlich</span>. <span class="bold">− </span>Die Sicherheit von Medizinprodukten muss voll und ganz gewährleistet werden, insbesondere auch im Kontext von klinischen Prüfungen. Die Transparenz und die wissenschaftliche Expertise der gewählten Verfahren sind grundlegend. Patientensicherheit und öffentliche Gesundheit müssen bei jeder Neuregelung mitbedacht und mitbeachtet werden und sollen die Grundlage aller Entscheidungen sein.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-249-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/35743.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Glenis Willmott (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. − </span>It is vital that all medical devices are completely safe, especially those that are going to be implanted into a patient's body. After recent scandals, such as the PIP breast implant case and problems with metal-on-metal hip replacements, it is clear that we need better regulation of medical devices to ensure patient safety. I therefore supported this report, which aims to ensure regulation of the medical devices industry is stricter and patients are better protected, without having a negative effect on innovation. Measures included in the new regulation include improved market surveillance, increased transparency and the introduction of a traceability system using unique identification numbers, so that in future every device can be traced and recalled if necessary. We also need more rigorous testing of devices before they enter the market, which is why I wanted to see pre-market approval for high-risk devices such as breast implants and pacemakers. I was disappointed that Conservative and Liberal Democrat MEPs gave in to heavy industry lobbying and helped to weaken this part of the proposal at committee stage.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-250-000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96802.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jacek Włosowicz (EFD), </span></span>  <span class="italic">na piśmie</span><span class="bold">. − </span>Opierając się na definicji zawartej w dyrektywie 93/43/EWG, wyrób medyczny to „narzędzie, przyrząd, aparat, sprzęt, materiał lub inny artykuł stosowany samodzielnie lub w połączeniu, włączając oprogramowanie niezbędne do właściwego stosowania wyrobu, przeznaczone przez wytwórcę do stosowania u ludzi w celu: </p>
<p class="contents">• diagnozowania, zapobiegania, monitorowania, leczenia lub łagodzenia przebiegu chorób, </p>
<p class="contents">• diagnozowania, monitorowania, leczenia, łagodzenia lub kompensowania skutków urazów lub upośledzeń, </p>
<p class="contents">• badania, zastępowania lub modyfikowania budowy anatomicznej lub prowadzenia procesu fizjologicznego, </p>
<p class="contents">• regulacji poczęć, </p>
<p class="contents">i jednocześnie, który nie osiąga swojego zasadniczego zamierzonego działania w ciele lub na ciele ludzkim środkami farmakologicznymi, immunologicznymi lub metabolicznymi, lecz którego działanie może być przez nie wspomagane”. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-250-002"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96803.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Zbigniew Ziobro (EFD), </span></span>  <span class="italic">na piśmie</span>. <span class="bold">− </span>Dziękuję sprawozdawcy za przedstawienie sprawozdania o wyrobach medycznych. Jak wiadomo, wyroby te są niezbędne dla opieki zdrowotnej. Dzięki innowacyjności oraz różnorodności tej branży następuje zarówno poprawa skuteczności, jak i jakości opieki zdrowotnej. To również ważna branża o strategicznym znaczeniu dla gospodarek państw członkowskich. Kluczowe jest przede wszystkim zapewnienie bezpieczeństwa pacjentom. W tym celu niezbędne są ogólnodostępne informacje oraz ostrzeżenia o wyrobach medycznych mogących stanowić zagrożenie dla zdrowia. Ważne jest także podjęcie natychmiastowych działań w sytuacji, kiedy dany wyrób medyczny okaże się szkodliwy.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-250-003"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/111589.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Inês Cristina Zuber (GUE/NGL), </span></span>  <span class="italic">por escrito</span>. <span class="bold">− </span>Depois dos problemas graves verificados em vários países relativamente aos implantes mamários de silicone e aos implantes metálicos para as ancas, a Comissão Europeia elaborou uma proposta de regulamento sobre dispositivos médicos. Os dispositivos médicos considerados neste regulamento são considerados qualquer instrumento, aparelho, equipamento, máquina, implante ou <span class="italic">software</span> desenhados para diagnóstico, prevenção, monitorização ou tratamento de doenças, que vão desde as simples ligaduras até aos instrumentos mais complexos de suporte de vida como <span class="italic">pacemakers</span> ou implantes de vária ordem. O regulamento pretende aumentar a transparência dos processos, melhorar a informação aos pacientes, melhorar o controlo sob os organismos notificados, subcontratados e subsidiados, estabelecer requisitos para pessoal interno das autoridades nacionais e organismos notificados e regras mais restritas para os dispositivos que podem ser reprocessados. O resultado final da votação enfraqueceu substancialmente a proposta que saiu da comissão especializada. Ainda assim votámos favoravelmente.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-250-004"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/23894.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Anna Záborská (PPE), </span></span>  <span class="italic">písomne</span><span class="bold">. − </span>Návrh som podporila, pretože jeho cieľom je vysoká úroveň ochrany zdravia pacientov aj personálu obsluhujúceho zdravotnícke pomôcky. Myslím si, že zdravotnícke pomôcky nachádzajúce sa na trhu Európskej únie musia byť bezpečné nielen pre pacientov, ale aj pre zdravotníckych pracovníkov, ktorí ich používajú či obsluhujú, a pre laické osoby, ktoré s nimi prídu do kontaktu. Ohrození pri tom nie sú len zdravotné sestry a lekári, no tiež ošetrovatelia, zamestnanci laboratórií a pomocný personál. Zdravotnícke pomôcky musia podliehať najprísnejšej kontrole. Výrobcovia originálnych aj repasovaných pomôcok by mali zhromažďovať údaje o tom, či spĺňajú všetky požiadavky na funkčnú spôsobilosť a bezpečnosť. Ale zároveň ani prípadné zvýšené náklady nesmú ohroziť dostupnosť týchto pomôcok pre všetkých, ktorí ich potrebujú.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
